Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

Exclusion Criteria

• •Prior receipt of an FGFR inhibitor.
• •Receipt of anticancer medications or investigational drugs for any indication or reason within 28 days before first dose of study drug.
• •Participants may have had treatment for an unlimited number of prior relapses but must not have had prior bevacizumab or other VEGF/VEGFR inhibitors (exception: prior bevacizumab is allowed if it was administered for the treatment of radiation necrosis rather than progressive tumor and was stopped at least 12 weeks prior to MRI showing tumor progression).
• •Concurrent anticancer therapy
• •Candidate for potentially curative surgery.
• •Dexamethasone (or equivalent) \> 4 mg daily at the time of study registration
• •Current evidence of clinically significant corneal or retinal disorder as confirmed by ophthalmologic examination.
• •Diffuse leptomeningeal disease.
• •Radiation therapy administered within 12 weeks before enrollment/first dose of study drug.
• •Known additional malignancy that is progressing or requires active systemic treatment.